title: Acanthosis nigricans during treatment with aripiprazole.
abstract: Aripiprazole is typically regarded as a metabolically sparing agent, in contrast to other second-generation antipsychotics, which are widely known to lead to weight gain and increase the cardiometabolic risk. We report for the first time the emergence of Acanthosis nigricans, a dermatological correlate of insulin resistance, during treatment with aripiprazole in an adolescent with a family history of diabetes mellitus.
authors.affiliation: 1Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY 2Department of Psychiatry, Hofstra North Shore, Long Island Jewish School of Medicine, Hempstead, NY 3Department of Psychiatry, Albert Einstein College of Medicine, Bronx, NY 4Department of Psychiatry, Feinstein Institute for Medical Research, Manhasset, NY.
authors.forename: Peter
authors.initials: P
authors.lastname: Manu
authors.forename: Zainab
authors.initials: Z
authors.lastname: Al-Dhaher
authors.forename: Navin
authors.initials: N
authors.lastname: Dargani
authors.forename: Christoph U
authors.initials: CU
authors.lastname: Correll
mesh_terms: D000052:Acanthosis Nigricans / Q000139:chemically induced*; D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068180:Aripiprazole; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D015363:Quinolones / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole